{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T20:04:08Z","timestamp":1789070648037,"version":"build-2803163510"},"reference-count":35,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Mycosis fungoides (MF) and S\u00e9zary syndrome (SS) are common subtypes of cutaneous T\u2010cell lymphoma that primarily affect the skin but may spread to the lymph nodes, viscera and blood. The symptom burden may compromise health\u2010related quality of life (HRQL). The phase 3 MAVORIC study (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      identifier NCT01728805) in patients with relapsed\/refractory MF\/SS reported improved HRQL with mogamulizumab compared with vorinostat.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Use baseline (pre\u2010treatment) data from the MAVORIC study to describe the symptom burden of MF\/SS and identify characteristics associated with worse HRQL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were from 372 adults with stage IB\u2013IVB histologically confirmed relapsed\/ refractory MF or SS. Associations between demographic and medical history variables and worse HRQL (Skindex\u201029, ItchyQol and Functional Assessment of Cancer Therapy \u2013 General [FACT\u2010G]) were determined by regression models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In the cohort of 372 adults, 70% were white; 42% were female; mean age was 63 (SD 13.0) years. Fifty\u2010five per cent had MF and 45% had SS; 77% had advanced (stage IIB\u2013IV) disease, involving the skin in all patients and the blood and\/or nodes in 66%. HRQL scores showed impairment versus normative means (where available), with the greatest impact on Symptoms and Emotions in the Skindex\u201029, Functioning in the ItchyQol, and Functional Wellbeing in the FACT\u2010G. In regression analysis, worse HRQL across all domains and total score was associated with being female and younger, worse mSWAT score and worse itch for the Skindex\u201029 (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009352), and being female, younger, Black\/African American, worse performance status and worse itch for the ItchyQol (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009369). Associations across domains and total score were not found for the FACT\u2010G. Associations between domains and demographic\/medical history were seen for all instruments.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The symptoms of advanced MF\/SS compromise all HRQL domains. Treatment goals and therapeutic choice should be informed by individual patients' disease burden.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.20357","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T09:32:35Z","timestamp":1727170355000},"page":"833-845","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Health\u2010related quality of life in cutaneous T\u2010cell lymphoma: A post hoc analysis of a phase 3 trial in mycosis fungoides and S\u00e9zary syndrome"],"prefix":"10.1111","volume":"39","author":[{"given":"P. L.","family":"Ortiz Romero","sequence":"first","affiliation":[{"name":"Hospital 12 de Octubre, Medical School University Complutense  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. H.","family":"Kim","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine and Cancer Institute  Stanford CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Molloy","sequence":"additional","affiliation":[{"name":"Tallaght University Hospital\/Trinity College Dublin  Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4185-9586","authenticated-orcid":false,"given":"P.","family":"Quaglino","sequence":"additional","affiliation":[{"name":"University of Turin  Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Scarisbrick","sequence":"additional","affiliation":[{"name":"University Hospital Birmingham  Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Thornton","sequence":"additional","affiliation":[{"name":"Susan Thornton, Cutaneous Lymphoma Foundation  Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Sandilands","sequence":"additional","affiliation":[{"name":"Kyowa Kirin International  Marlow UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. E.","family":"Dent","sequence":"additional","affiliation":[{"name":"Chilli Consultancy  Salisbury UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3454-9491","authenticated-orcid":false,"given":"A.","family":"Nixon","sequence":"additional","affiliation":[{"name":"Chilli Consultancy  Salisbury UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Williams","sequence":"additional","affiliation":[{"name":"Kyowa Kirin International  Marlow UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1388-5330","authenticated-orcid":false,"given":"M. M.","family":"Shinohara","sequence":"additional","affiliation":[{"name":"University of Washington and Fred Hutchinson Cancer Center  Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,9,24]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.8829.1"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-881268"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2008.0033"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0789"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-021-06241-6"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ski2.45"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2012.01.012"},{"key":"e_1_2_14_9_1","unstructured":"European Medicines Agency.Reflection paper on the regulatory guidance for the use of health\u2010related quality of life (HRQL) measures in the evaluation of medicinal products. Available at:https:\/\/www.ema.europa.eu\/en\/documents\/scientific\u2010guideline\/reflection\u2010paper\u2010regulatory\u2010guidance\u2010use\u2010health\u2010related\u2010quality\u2010life\u2010hrql\u2010measures\u2010evaluation_en.pdf"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.5967"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22252"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/jvc2.39"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18089"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08992.x"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-116346"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.09.003"},{"key":"e_1_2_14_17_1","doi-asserted-by":"crossref","unstructured":"ZinzaniPL Ortiz\u2010RomeroP LimaM HuenA.Health\u2010related quality of life effect of mogamulizumab by patient blood involvement. EORTC CL group meeting 20\u201321 and virtual October 2021; Marseille France 21 S249.","DOI":"10.1016\/S2152-2650(21)01565-2"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30379-6"},{"key":"e_1_2_14_19_1","volume-title":"Quality of life in cutaneous T\u2010cell lymphoma subjects treated with anti\u2010CCR4 monoclonal antibody mogamulizumab versus vorinostat: Results from the phase 3 MAVORIC trial","author":"Porcu P","year":"2018"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2011.11.003"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.04.006"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2517-6161.1996.tb02080.x"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2011.138"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.5"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1891"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28758"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.141.3.325"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(21)00680-8"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/JW9.0000000000000085"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12909"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2011.614636"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-20-1054"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.21037\/jgo.2019.02.04"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(00)00447-0"},{"key":"e_1_2_14_35_1","doi-asserted-by":"publisher","DOI":"10.2196\/11302"},{"key":"e_1_2_14_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18710"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.20357","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T02:59:45Z","timestamp":1744253985000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.20357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,24]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1111\/jdv.20357"],"URL":"https:\/\/doi.org\/10.1111\/jdv.20357","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,24]]},"assertion":[{"value":"2024-03-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}